Publications

Continued JAK Inhibitor Treatment on the Risk of Recurrent Herpes Zoster Reactivation in Patients with Immune-mediated Inflammatory Diseases: A Nationwide Population-based Study in South Korea

Semin Arthritis Rheum 2024 doi 10.1016/j.semarthrit.2024.152362 Epub ahead of print

Kim YE,

Kim YJ,

Jeong DH,

Kim S,

Kim MJ,

Kim HH,

Jo KW,

Park SH,

Hong S

This real-world study by Kim, et al. found no significant relationship between continued JAK inhibitor therapy in patients with IMIDs and the risk of subsequent recurrent HZ reactivation. They also found no significant difference in the number of days patients were treated for HZ in the JAK inhibitor continuation and discontinuation groups.

Keywords:

• JAK,
• Real-World,
• Safety

トファシチニブと悪性腫瘍リスク: Routine Care Patients With Rheumatoid Arthritis (STAR-RA) 試験からの結果

Arthritis Rheumatol. 2022;74:1648–1659 doi: 10.1002/art.42250

Khosrow-Khavar F,

Desai RJ,

Lee H,

Lee SB,

Kim SC

Large, population-based, real-world cohort of study in patients with RA finds tofacitinib not to be associated with an increased risk of malignancies, in comparison to TNFi agents, although a numerically increased risk of malignancies was observed in older patients with risk factors for cardiovascular disease.

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Malignancy

乾癬または乾癬性患者でウステキヌマブまたは他の生物学的製剤を開始後の重篤感染症による入院リスク

Arthritis Care Res (Hoboken) 2022 doi: 10.1002/acr.24630

Jin Y,

Lee H,

Lee MP,

Landon JE,

Merola JF,

Desai RJ,

Kim SC

In this investigation it was concluded that other biologics and apremilast were associated with a 1.4- to 3-times higher risk of hospitalisation for serious infections in PsO/PsA patients when compared to ustekinumab. These findings should be considered in the safety profile of these therapies when selecting appropriate treatment regimens in patients with PsO/PsA.

Keywords:

• IL-12,
• Ustekinumab,
• Safety,
• Infections

Tofacitinib と 心血管イベントリスク: 関節リウマチ患者 の日常臨床における結果 (STAR-RA)

Ann Rheum Dis. 2022 Jan 13. Epub ahead of print doi: 10.1136/annrheumdis-2021-221915

Khosrow-Khavar F,

Kim SC,

Lee H,

Lee SB,

Desai RJ

Real-world evidence finds no increased risk of CV outcomes with tofacitinib, in comparison with TNFi, in patients with RA. However, an elevated risk of CV outcomes cannot be ruled out in patients with CV risk factors or history of CVD.Recent post-marketing findings from the ‘ORAL Surveillance’ trial have raised concerns that tofacitinib, in comparison with TNFi, may increase the risk of CV disease in patients with RA who are at least 50 years of age and with at least one risk factor for CVD. To ...

Keywords:

• JAK,
• Tofacitinib,
• Real-World,
• Cardiovascular

関節リウマチ患者におけるtofacitinibの深部血栓症　　リスク: 人口基盤のコホート研究

Rheumatology (Oxford). 2021 Mar 22:keab294. Epub ahead of print. DOI: 10.1093/rheumatology/keab294

Desai RJ,

Pawar A,

Khosrow-Khavar F,

Weinblatt ME,

Kim SC

A population-based cohort study of 87,653 RA patients has found no evidence for an increased risk of venous thromboembolism (VTE) for tofacitinib, versus TNFis, in patients with RA.The introduction of JAKinibs, almost a decade ago, has provided an important oral option for the treatment of RA. However, in recent years, a safety concern, relating to incidence of VTE after treatment, has emerged. Consequently, both the US and European regulatory authorities now recommend caution for use of tofacit...

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Real-World

トファシチニブと腫瘍壊死因子阻害薬では同等の血栓塞栓症リスク: 関節リウマチ患者のコホート研究

Desai RJ, et al. Arthritis Rheumatol. 2019 June;71(6):892-900.

Desai RJ,

Pawar A,

Weinblatt ME,

Kim SC

Occurrences of venous thromboembolism (VTE) in 50, 865 RA patients initiating Tofacitinib (TOF) or a TNF inhibitor (TNFi) was infrequent. No significant risk of VTE for TOF versus TNFi was observed.Safety concerns of JAK inhibitor BARI include potentially increased risk of VTE at the higher 4 mg dose. It’s unclear if this is attributable to JAK-inhibition and extends to TOF. This study compared the risk of VTE with TOF, versus TNFi in real-world settings with RA patients.RA patients initiating T...

Keywords:

• JAK,
• Tofacitinib,
• Safety

Successful Treatment of Arthritis Induced by Checkpoint Inhibitors with Tocilizumab: a Case Series

Ann Rheum Dis 2017;76:2061-64. doi: 10.1136/annrheumdis-2017-211560

Kim ST,

Tayar J,

Trinh VA,

Suarez-Almazor M,

Garcia S,

Hwu P,

Johnson DH,

Uemura M,

Diab A

This case series evaluated the use of tocilizumab (TCZ) as an effective treatment for patients who develop arthritis as an adverse event (AE) of immune checkpoint inhibitor (ICI) cancer treatment. Results suggested that TCZ was an effective treatment, as it reduced the arthritis disease progression.ICIs have been defined as a revolutionary treatment for metastatic melanomas; however, a common AE is the development of polyarthritis. Current arthritis treatments reduce the efficiency of ICI therap...

Cardiovascular Safety of Tocilizumab versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis – a Multi-database Cohort Study

Arthritis Rheumatol 2017 Feb 28. doi: 10.1002/art.40084

Kim SC,

Solomon DH,

Rogers JR,

Gale S,

Klearman M,

Sarsour K and Schneeweiss S

This multi-database population-based US cohort study found no evidence of an increased cardiovascular (CV) risk among RA patients who switched from a different biologic drug or tofacitinib to tocilizumab (TCZ) versus to a TNF inhibitor (TNFi).The study used claims data in patients with RA newly starting treatment with TCZ or a TNFi from three large databases: Medicare (n=7397), PharMetrics (n=8119) and MarketScan (n=12512). Included within the analysis were 9218 TCZ initiators propensity-score m...

Keywords:

• IL-6,
• Tocilizumab,
• Cardiovascular,
• Review